Dr. Matthew Galsky, M.D.
Claim this profileIcahn School of Medicine at Mount Sinai
Area of expertise
Bladder Cancer
Matthew Galsky, M.D. has run 8 trials for Bladder Cancer. Some of their research focus areas include:
Cancer
Matthew Galsky, M.D. has run 5 trials for Cancer. Some of their research focus areas include:
Affiliated Hospitals
Icahn School Of Medicine At Mount Sinai
Mount Sinai Medical Center
Clinical Trials Matthew Galsky, M.D. is currently running
FX-909
for Bladder Cancer
This trial tests a new tablet called FX-909 for safety and proper dosage in patients with advanced solid tumors, especially advanced urothelial carcinoma. Doctors will closely monitor patients to understand how the drug works and its effects on the body and tumors.
Recruiting
1 award
Phase 1
Disitamab Vedotin + Pembrolizumab vs Chemotherapy
for Bladder Cancer
This study will enroll participants with urothelial cancer (UC). UC can include cancer of the bladder, kidney, or the tubes that carry pee through the body (ureter, urethra). This study will try to find out if the drugs disitamab vedotin with pembrolizumab works better than platinum-containing chemotherapy to treat patients with UC. This study will also test what side effects happen when participants take these drugs together. A side effect is anything a drug does to the body besides treating the disease. Participants in this study will have cancer that has spread through the body (metastatic) or spread near where it started (locally advanced). In this study, there are 2 different groups. Participants will be assigned to a group randomly. Participants in the disitamab vedotin arm will get the study drug disitamab vedotin once every two weeks and pembrolizumab once every 6 weeks. Participants in the standard of care arm will get gemcitabine once a week for 2 weeks with either cisplatin or carboplatin once every 3 weeks.
Recruiting
2 awards
Phase 3
More about Matthew Galsky, M.D.
Clinical Trial Related
5 years of experience running clinical trials · Led 16 trials as a Principal Investigator · 5 Active Clinical Trials
Treatments Matthew Galsky, M.D. has experience with
- Pembrolizumab
- Nivolumab
- Carboplatin
- Cisplatin
- Ipilimumab
- Gemcitabine
Breakdown of trials Matthew Galsky, M.D. has run
Bladder Cancer
Cancer
Transitional Cell Carcinoma
Prostate Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Matthew Galsky, M.D. specialize in?
Matthew Galsky, M.D. focuses on Bladder Cancer and Cancer. In particular, much of their work with Bladder Cancer has involved Stage III patients, or patients who are Stage IV.
Is Matthew Galsky, M.D. currently recruiting for clinical trials?
Yes, Matthew Galsky, M.D. is currently recruiting for 5 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Matthew Galsky, M.D. has studied deeply?
Yes, Matthew Galsky, M.D. has studied treatments such as Pembrolizumab, Nivolumab, Carboplatin.
What is the best way to schedule an appointment with Matthew Galsky, M.D.?
Apply for one of the trials that Matthew Galsky, M.D. is conducting.
What is the office address of Matthew Galsky, M.D.?
The office of Matthew Galsky, M.D. is located at: Icahn School of Medicine at Mount Sinai, New York, New York 10029 United States. This is the address for their practice at the Icahn School of Medicine at Mount Sinai.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.